Skip to content

Bharat Biotech gets nod to use Intra Nasal COVID vaccine in India

Dr. Krishna Ella, chairman and managing director, Bharat Biotech called the vaccine a “global game changer”

Photo by CDC / Unsplash

Bharat Biotech International Limited (BBIL) has received approval for India's first intra nasal COVID vaccine, iNCOVACC, under Restricted Use in Emergency Situation for ages 18 and above in India, the company announced on Tuesday.

According to the biotech company, the specially formulated nasal vaccine, developed in collaboration with Washington University St. Louis, yielded successful results in the three phase clinical trails, during which it was tested against the Omicron and the previous variants of the COVID-19 virus.

This post is for paying subscribers only


Already have an account? Log in